Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; osteoporosis, including Actemra, Edirol, and Bonviva; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.
The current price of CUP.STU is €46.26 EUR — it has decreased by -0.81% in the past 24 hours. Watch Chugai Pharmaceutical stock price performance more closely on the chart.
What is Chugai Pharmaceutical stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Chugai Pharmaceutical stocks are traded under the ticker CUP.STU.
Is Chugai Pharmaceutical stock price growing?▼
CUP.STU stock has fallen by -7.96% compared to the previous week, the month change is a -9.82% fall, over the last year Chugai Pharmaceutical has showed a +13.02% increase.
How many employees does Chugai Pharmaceutical have?▼
As of April 10, 2026, the company has 5,026 employees.
In which sector is Chugai Pharmaceutical located?▼
Chugai Pharmaceutical operates in the Health Care sector.
When did Chugai Pharmaceutical complete a stock split?▼
Chugai Pharmaceutical has not had any recent stock splits.
Where is Chugai Pharmaceutical headquartered?▼
Chugai Pharmaceutical is headquartered in Chuo, US.